Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study;Eficacia y Seguridad de Mirtazapina en el Síndrome de Fibromialgia: Estudio Piloto, Aleatorio, y Control Placebo

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages 921-932

  Yeephu, Suwimon ^a   Suthisisang, Chuthamanee ^a   Suttiruksa, Saithip ^a   Prateepavanich, Pradit ^b   Limampai, Patchara ^b   Russell, Irwin Jon ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE; PLACEBO;

ADULT; ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; FOLLOW UP; HAMILTON SCALE; HEART RATE; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WEIGHT GAIN; XEROSTOMIA;

ADULT; DIZZINESS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FIBROMYALGIA; HUMANS; MIANSERIN; MIDDLE AGED; PAIN MEASUREMENT; PILOT PROJECTS; PROSPECTIVE STUDIES; SYNDROME; TREATMENT OUTCOME;

EID: 84880069235     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R725     Document Type: Article

References (53)

1. Russell IJ, Raphael KG. Fibromyalgia syndrome: presentation, diagnosis, differential diagnosis, and vulnerability. CNS Spectr 2008;13(suppl 5):6-11.
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
3. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
4. Nisell R, Kosek E. New insights in fibromyalgia: a review. J Clin Rheumatol Musculoskelet Med 2011;2:57-65.
5. Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther 2008;10:R17. doi: 10.1186/ar2368
6. Felson DT. Comparing the prevalence of rheumatic diseases in China with the rest of the world. Arthritis Res Ther 2008;10:106. doi: 10.1186/ar2369
7. Scudds RA, Li EK-M, Scudds RJ. The prevalence of fibromyalgia syndrome in Chinese people in Hong Kong. J Musculoskelet Pain 2006;14: 3-11. doi: 10.1300/J094v14n02_02
8. Russell IJ. The prevalence of the fibromyalgia syndrome in China. J Musculoskelet Pain 2006;14:1-2. doi: 10.1300/J094v14n02_01
9. Gran JT. The epidemiology of chronic generalized musculoskeletal pain. Best Pract Res Clin Rheumatol 2003;17:547-61. doi: 10.1016/S1521-6942(03)00042-1
10. Staud R. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthritis Res Ther 2006;8:208. doi: 10.1186/ar1950
11. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001;91:165-75.
12. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46:1333-43. doi: 10.1002/art.10225
13. Russell IJ. Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis. Rheum Dis Clin N Am 2009;35:421-35.
14. Arnold LM. Biology and therapy of fibromyalgia: new therapies in fibromyalgia. Arthritis Res Ther 2006;8:212. doi: 10.1186/ar1971
15. Arnold LM, Clauw D, McCarberg BH: FibroCollaborative. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc 2011;86:457-64. doi: 10.4065/mcp.2010.0738
16. Recla JM. New and emerging therapeutic agents for the treatment of fibromyalgia: an update. J Pain Res 2010;3:89-103. doi: 10.2147/JPR.S6792
17. Boomershine CS. Pregabalin for the management of fibromyalgia syndrome. J Pain Res 2010;3:81-8. doi: 10.2147/JPR.S7884
18. Russell IJ. Fibromyalgia syndrome: approach to management. CNS Spectr 2008;13 (suppl 5):27-33.
19. Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res 2012;64:597-606. doi: 10.1002/acr.21595
20. Kent JM. SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-8. doi: 10.1016/S0140-6736(99)11381-3
21. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission (abstract). Int Clin Psychopharmacol 1995;10 (suppl 4):19-23.
22. Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001;7:249-64.
23. Brannon GE, Stone KD. The use of mirtazapine in a patient with chronic pain. J Pain Symptom Manag 1999;18:382-5.
24. Freynhagen R, Muth-Selbach U, Lipfert P, et al. The effect of mirtaza-pine in patients with chronic pain and concomitant depression. Curr Med Res Opin 2006;22:257-64. doi: 10.1185/030079906X80486
25. Arnold P, Vuadens P, Kuntzer T, Gobelet C, Deriaz O. Mirtazapine decreases the pain feeling in healthy participants. Clin J Pain 2008;24:116-9. doi: 10.1097/AJP.0b013e318159f94a
26. Samborski W, Lezanska-Szpera M, Rybakowski JK. Effects of antidepressant mirtazapine on fibromyalgia symptoms. Rocz Akad Med Bialymst 2004;49:265-9.
27. Samborski W, Lezanska-Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 2004;37: 168-70. doi: 10.1055/s-2004-827172
28. Calis KA, Sidawy EN, Young LR. Clinical analysis of adverse drug reactions. In: Atkinson AJ Jr, Abernethy DR, Daniels CE, Dedrick RL, Markey SP, eds. Principles of clinical pharmacology. 2nd ed. Burlington, MA: Academic Press, 2007:389-402.
29. Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry 2004;161:2163-77.
30. Mease P, Arnold LM, Choy EH, et al. OMERACT Fibromyalgia Working Group: fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009;36:2318-29. doi: 10.3899/jrheum.090367
31. Kim SW, Shin IS, Kim JM, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 2008;62:75-83. doi: 10.1111/j.1440-1819.2007.01778.x
32. Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manag 2002;23:442-7.
33. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004;62:1706-11.
34. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 1997;96(suppl 391):31-7.
35. Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects-a possible opioid involvement in severe depression? J Mol Neurosci 2002;18:143-9. doi: 10.1385/JMN:18:1-2:143
36. Becker S, Schweinhardt P. Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat 2012;2012:741746. doi: 10.1155/2012/741746
37. Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance of group differences in chronic pain clinical trial: IMMPACT recommendations. Pain 2009;146:238-44. doi: 10.1016/j.pain.2009.08.019
38. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2005;52:1264-73. doi: 10.1002/art.20983
39. Wright A, Luedtke KE, VanDenBerg C. Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy. J Pain Res 2011;4:1-10. doi: 10.2147/JPR.S12866
40. Roizenblatt S, Neto NSR, Tufik S. Sleep disorders and fibromyalgia. Curr Pain Headache Rep 2011;15:347-57. doi: 10.1007/s11916-011-0213-3
41. Schmid DA, Wichniak A, Uhr M, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 2006;31:832-44. doi: 10.1038/sj.npp.1300923
42. Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002;25:677-9.
43. Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002;46:197-201. doi: 10.1159/000067812
44. Mease P, Arnold LM, Bennett RM, et al. Fibromyalgia syndrome. J Rheumatol 2007;34:1415-25.
45. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009 36:1304-11. doi: 10.3899/jrheum.081090
46. Wheatley DP, Moffaert M, Timmerman L, Kremer CME, the Mirtaza-pine-Fluoxetine Study Group. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 1998;59:306-12.
47. Hongsanguansri S, Putthisri S, Zartrungpak S, Kongsakon R. Efficacy and safety of mirtazapine in Thai patients with major depressive disorder. J Psychiatr Assoc Thailand 2001;46:179-86.
48. Szegedi A, Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Exp Opin Pharmacother 2005;6:631-41. doi: 10.1517/14656566.6.4.631
49. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17:10-21. doi: 10.1002/j.1875-9114.1997.tb03674.x
50. Watanabe N, Omori IM, Nakagawa A, et al. Safety reporting and adverseevent profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010;24:35-53. doi: 10.2165/11319480-000000000-00000
51. Sakata T, Yoshimatsu H, Kurokawa M. Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition 1997;13:403-11.
52. Halford JCG, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007;67:27-55.
53. Arnold DM, Burns KEA, Adhikari NKJ, et al. The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med 2009;37(suppl):S69-S74. doi: 10.1097/CCM.0b013e3181920e33